GentiBio
Founded 2020 · 43 employees on LinkedIn · 4 known investors
GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Founders & leadership
GentiBio was founded in 2020 by Jane Buckner, Chandra Patel, David Rawlings, and Andy Scharenberg.
JB
Jane BucknerScientific Co-founder (President, Benaroya Research Institute)
CP
Chandra PatelCo-founder & SVP, Research and Development Operations
DR
David RawlingsScientific Co-founder and Senior Scientific Advisor
AS
Andy ScharenbergScientific Co-founder, SAB Chair
AW
Andy WalkerPresident and CEO
TW
Tom WickhamChief Scientific Officer
MB
Mark BachChief Medical Officer
Investors · 4
Competitors · 3
by search overlap
Bridgebio58 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Bioworld49 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AskBio37 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Companies competing with GentiBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does GentiBio do?
- GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
- Who founded GentiBio?
- GentiBio was founded by Jane Buckner, Chandra Patel, David Rawlings, Andy Scharenberg in 2020.
- Who are GentiBio's investors?
- GentiBio's investors include Novartis Venture Fund, OrbiMed, JDRF T1D Fund, RA Capital.